Kantonsspital St.Gallen
login

Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge

M Krolik, Lucia Csepregi, Fabienne Hartmann, Céline Engetschwiler & Lukas Flatz

abstract Reverse genetically engineered recombinant lymphocytic choriomeningitis virus (rLCMV) is a novel vaccine vector platform. Here, we investigate the safety and efficacy of rLCMV in mice lacking a functional type I interferon system with high susceptibility to viral infections. Propagation-deficient rLCMV vector expressing ovalbumin as a model antigen is cleared from type I interferon receptor-deficient mice (Ifnar) within seven days post vaccination. In Ifnar, induction of vaccine antigen specific T cells is delayed compared to wild type animals. However, immunization of Ifnar results in potent memory formation and generates multifunctional cytotoxic CD8 T cells. Most importantly, Ifnar vaccinated with rLCMV are protected from a challenge with the aggressive LCMV Clone 13. Our data provide evidence for an excellent safety profile with maintained efficacy in immunocompromised animals.
   
citation krolik m, Csepregi L, Hartmann F, Engetschwiler C, Flatz L. Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge. Vaccine 2021; 39:1257-1264.
   
type journal paper/review (English)
date of publishing 29-01-2021
journal title Vaccine (39/8)
ISSN electronic 1873-2518
pages 1257-1264
PubMed 33518468
DOI 10.1016/j.vaccine.2021.01.047